Viewing Study NCT03483103

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:48 PM
Ignite Modification Date: 2026-07-06 @ 1:45 AM
Study NCT ID: NCT03483103
Status: COMPLETED
Last Update Posted: 2023-12-20
First Post: 2018-03-23
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma, Non-Hodgkin View
None Lymphoma, Nonhodgkin View
None Lymphoma, B-Cell View
None Lymphoma, Large B-Cell, Diffuse View
Keywords:

Keywords

Keyword Brief Keyword Text View
None JCAR017 View
None lisocabtagene maraleucel View
None NHL View
None chimeric antigen receptor View
None CAR View
None CAR T cell View
None autologous T cell therapy View
None immunotherapy View
None cell therapy View
None liso-cel View